CBD & Hemp Cosmetics

CBD and hemp are among the most sought-after ingredients in skincare, and among the most legally complicated. They sit where cosmetics law, narcotics control and medicines law overlap, and the single most important fact is that the exact form of the ingredient, not the word “CBD”, decides whether a product is legal.

The narcotics prohibition

Entry 306 of Annex II to the Cosmetics Regulation prohibits cannabis, cannabis resin, and extracts and tinctures of cannabis, reflecting the 1961 Single Convention on Narcotic Drugs. The direct consequence is that cannabidiol prepared as an extract or tincture of the cannabis plant is not permitted in cosmetics, regardless of how it is marketed. This is the trap many brands fall into, because a great deal of commercial CBD is exactly that, a cannabis extract.

The permitted forms

Compliant CBD comes from forms that fall outside the prohibition. Synthetically produced cannabidiol has its own entry in the CosIng database and is permitted, and CBD supplied as an isolate that is not the prohibited extract or tincture is treated separately from entry 306. Ingredients from the seeds and stems rather than the flowering tops, Cannabis sativa seed oil, seed extract, seedcake and stem-derived materials, are permitted, provided the tetrahydrocannabinol (THC) content stays within the hemp limit of 0.2%. The Court of Justice confirmed in its 2020 Kanavape ruling that lawfully produced CBD is not in itself a narcotic, but that ruling did not override the Annex II prohibition on the specific cannabis derivatives, so a brand has to work within the CosIng entries rather than rely on the judgment alone.

THC and controlled cannabinoids

THC and other controlled cannabinoids bring a second layer of law. In the UK the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001 apply, and a CBD cosmetic must qualify as an “exempt product”, meaning its controlled-cannabinoid content stays within the regulatory limit. The practical difficulty is that extracting CBD tends to co-extract trace controlled cannabinoids, so a certificate of analysis verifying THC and controlled-cannabinoid levels is essential evidence, not an optional extra.

Not a novel food, and no medicinal claims

The novel-food regime that causes so much difficulty for CBD applies to ingestible products, not to topical cosmetics, so a CBD cream or balm needs a CPSR, a Responsible Person and a notification rather than novel-food authorisation. What it must not do is make medicinal claims: a claim to treat pain, inflammation or a skin disease moves the product into the medicines regime and out of cosmetics entirely.

How we help

We make sure the CBD source is a compliant one, synthetic or seed and stem derived rather than a prohibited extract, verify the THC and controlled-cannabinoid content against the limits using certificate-of-analysis data, prepare the safety report and act as Responsible Person, and set the claims firmly on the cosmetic side of the medicines line. The result is a CBD product that can actually be sold, not one that is withdrawn at the first enforcement check.